GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
PHARMATHENE INC (PIP) [hlAlert]

Rating:
Mkt Outperform
PIP
up 151.55 %

PHARMATHENE INC (PIP) upgraded to Mkt Outperform with price target $7 by Rodman & Renshaw

Posted on: Monday,  Jun 4, 2012  9:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform PHARMATHENE INC (AMEX: PIP) on 06/04/2012. Previously Rodman & Renshaw rated Mkt Underperform PHARMATHENE INC (AMEX: PIP)
on 01/04/2011., when the stock price was $4.05. Since then, PHARMATHENE INC has lost 60.25% as of 06/04/2012's recent price of $1.61.
If you would have followed the previous Rodman & Renshaw's recommendation on PIP, you would have gained 151.55% of your investment in 517 days.

PharmAthene, Inc. (PharmAthene), formerly Healthcare Acquisition Corp., is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. The Company has five product candidates in various stages of development, which include SparVax, Valortim, Protexia, RypVax and a third generation recombinant protective antigen (rPA) anthrax vaccine. SparVax is a second generation rPA anthrax vaccine. Valortim is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. Protexia mimics a natural bioscavenger for the treatment or prevention of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. RypVax is a recombinant dual antigen vaccine for pneumonic and bubonic plague. On April 2, 2008, the Company acquired Avecia?s biodefense vaccines business from Avecia Biologics Limited and certain of its affiliates.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/4/2012 9:25 AM Buy
None
1.61 7.00
as of 12/31/2012
1 Week down  -2.60 %
1 Month down  -7.43 %
3 Months down  -5.08 %
1 YTD down  -57.20 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/4/2011 8:25 AM Sell
None
4.05 2.50
2/3/2009 2:25 PM Buy
None
2.25 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy